Share
Share
Advancing the scientific understanding of kidney disease to inform healthcare practice and policy is at the core of Arbor Research’s history. Founded in 1996 in Ann Arbor, Michigan by three leaders in chronic kidney disease care and research, we were originally named the University Renal Research and Education Association (URREA). Arbor Research’s first project was the international Dialysis Outcomes and Practice Patterns Study (DOPPS), which has prospectively followed over 200,000 dialysis patients from more than 1,000 dialysis facilities across 24 countries worldwide during the past 28 years, resulting in over 325 publications. These DOPPS studies have informed the development, validation, and refining of clinical practice guidelines for millions of persons living with chronic kidney disease.
Arbor Research quickly expanded to include federally funded projects with a broad focus to improve patient health and health care delivery. This portfolio includes an enduring strength in tackling the issues of chronic kidney disease, including:
- A mix of federal contracts and grants to operate registries of chronic kidney disease and registries of organ transplant recipients, and assist living organ donors;
- A series of federal contracts to develop, maintain, implement, monitor, and evaluate Medicare quality measures and Medicare’s End-Stage Renal Disease Quality Incentive Program (the first Medicare value-based purchasing program to be implemented nationwide); and
- Federal grants to improve the scientific understanding of chronic kidney disease, including glomerulonephropathy and nephrotic syndrome, and better understand the current state and evolution of health care disparities.
Improving the lives of people with chronic kidney disease remains an important part of our mission. Arbor Research continues to contribute scientific discovery and the modernization of health care delivery, with recent innovations to slowing the progression of chronic kidney disease and increase patient-centered treatment options including home dialysis and increasing kidney transplantation.
Arbor Research is proud to celebrate World Kidney Day and join many in the collection goal of advancing equitable access to care and optimal medication practice.
January 8, 2025 — Christopher Spera, President and CEO of Arbor Research Collaborative for Health, announced the election of Bryan K. Johnson, JD, MBA to the Arbor Research board of directors in 2025. Mr. Johnson was a co-founder of Insight Policy Research in 2001. His strategic development, operational management, and financial oversight led the start-up
December 5, 2024 — Arbor Research Collaborative for Health is proud to announce an innovative collaboration with the Nephrology Associates of Northern Illinois and Indiana (NANI), the largest private nephrology practice in the United States. This partnership marks a significant milestone in advancing chronic kidney disease (CKD) research and management by leveraging NANI’s extensive patient-level
Arbor Research Collaborative for Health is excited to announce a partnership with CSL Vifor to launch a multinational registry designed to capture real-world outcomes of difelikefalin (Kapruvia®), a newly-approved treatment for chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis (HD) patients. Known as PARADIGM (PAn european Registry Addressing pruritus in DIalysis with a focus on Goal
The Health Resources and Services Administration (HRSA) has selected Arbor Research Collaborative for Health (Arbor Research) as one of 14 organizations who will lead the modernization of the Organ Procurement and Transplantation Network (OPTN). Arbor Research received one of the five initial efforts, focusing on improving patient safety and policy compliance systems and processes overseen